JP2017500338A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017500338A5 JP2017500338A5 JP2016541373A JP2016541373A JP2017500338A5 JP 2017500338 A5 JP2017500338 A5 JP 2017500338A5 JP 2016541373 A JP2016541373 A JP 2016541373A JP 2016541373 A JP2016541373 A JP 2016541373A JP 2017500338 A5 JP2017500338 A5 JP 2017500338A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compound
- formula
- methyl
- tumors
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1322755.8A GB201322755D0 (en) | 2013-12-20 | 2013-12-20 | Bicyclic heterocycle compounds and their uses in therapy |
| GB1322755.8 | 2013-12-20 | ||
| GB201406986A GB201406986D0 (en) | 2014-04-17 | 2014-04-17 | Bicyclic heterocycle compounds and their uses in therapy |
| GB1406986.8 | 2014-04-17 | ||
| PCT/GB2014/053778 WO2015092420A1 (en) | 2013-12-20 | 2014-12-19 | Bicyclic heterocycle compounds and their uses in therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019005876A Division JP6735369B2 (ja) | 2013-12-20 | 2019-01-17 | 二環式複素環化合物および治療におけるそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017500338A JP2017500338A (ja) | 2017-01-05 |
| JP2017500338A5 true JP2017500338A5 (OSRAM) | 2018-02-01 |
| JP6470756B2 JP6470756B2 (ja) | 2019-02-13 |
Family
ID=52134239
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016541373A Active JP6470756B2 (ja) | 2013-12-20 | 2014-12-19 | 二環式複素環化合物および治療におけるそれらの使用 |
| JP2019005876A Active JP6735369B2 (ja) | 2013-12-20 | 2019-01-17 | 二環式複素環化合物および治療におけるそれらの使用 |
| JP2020119260A Active JP7110279B2 (ja) | 2013-12-20 | 2020-07-10 | 二環式複素環化合物および治療におけるそれらの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019005876A Active JP6735369B2 (ja) | 2013-12-20 | 2019-01-17 | 二環式複素環化合物および治療におけるそれらの使用 |
| JP2020119260A Active JP7110279B2 (ja) | 2013-12-20 | 2020-07-10 | 二環式複素環化合物および治療におけるそれらの使用 |
Country Status (29)
| Country | Link |
|---|---|
| US (6) | US9783538B2 (OSRAM) |
| EP (2) | EP3083616B1 (OSRAM) |
| JP (3) | JP6470756B2 (OSRAM) |
| KR (1) | KR102408262B1 (OSRAM) |
| CN (3) | CN109336883B (OSRAM) |
| AU (2) | AU2014369446C1 (OSRAM) |
| BR (2) | BR122022015241B1 (OSRAM) |
| CA (1) | CA2933939C (OSRAM) |
| CY (1) | CY1124436T1 (OSRAM) |
| DK (1) | DK3083616T3 (OSRAM) |
| ES (1) | ES2883289T3 (OSRAM) |
| HR (1) | HRP20211406T1 (OSRAM) |
| HU (1) | HUE056297T2 (OSRAM) |
| IL (1) | IL246239B (OSRAM) |
| LT (1) | LT3083616T (OSRAM) |
| MX (1) | MX380469B (OSRAM) |
| MY (2) | MY193649A (OSRAM) |
| NZ (2) | NZ719905A (OSRAM) |
| PH (1) | PH12016501139B1 (OSRAM) |
| PL (1) | PL3083616T3 (OSRAM) |
| PT (1) | PT3083616T (OSRAM) |
| RS (1) | RS62301B1 (OSRAM) |
| RU (1) | RU2696310C1 (OSRAM) |
| SA (1) | SA516371360B1 (OSRAM) |
| SG (2) | SG10201808102WA (OSRAM) |
| SI (1) | SI3083616T1 (OSRAM) |
| SM (1) | SMT202100497T1 (OSRAM) |
| TW (1) | TWI649319B (OSRAM) |
| WO (1) | WO2015092420A1 (OSRAM) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201106814D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compounds |
| GB201106817D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
| GB201218850D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218862D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218864D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| US9980973B2 (en) | 2012-10-19 | 2018-05-29 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
| LT3083616T (lt) | 2013-12-20 | 2021-09-10 | Astex Therapeutics Limited | Bicikinių heterociklų junginiai ir jų panaudojimas terapijoje |
| CA2974651A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
| WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
| GB201506871D0 (en) | 2015-04-22 | 2015-06-03 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| PL3380086T3 (pl) | 2015-11-25 | 2022-02-21 | Io Therapeutics, Inc. | Oporne na cyp26 agonisty selektywne względem rar-alfa w leczeniu nowotworu |
| BR112018017195A2 (pt) * | 2016-02-24 | 2019-01-02 | Children's Hospital Of Eastern Ontario Research Institute Inc. | terapia de combinação de smc para o tratamento do câncer |
| CA3020792A1 (en) | 2016-04-20 | 2017-10-26 | Glaxosmithkline Intellectual Property Development Limited | Conjugates comprising ripk2 inhibitors |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| WO2017214575A1 (en) * | 2016-06-10 | 2017-12-14 | Io Therapeutics, Inc. | Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy |
| GB201610147D0 (en) | 2016-06-10 | 2016-07-27 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| IL297717A (en) | 2016-12-01 | 2022-12-01 | Arvinas Operations Inc | History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists |
| WO2019014492A1 (en) | 2017-07-13 | 2019-01-17 | Io Therapeutics, Inc. | RETINOID COMPOUNDS AND IMMUNOMODULATORY REXINOIDS IN COMBINATION WITH IMMUNE MODULATORS FOR IMMUNOTHERAPY OF CANCER |
| KR20200044889A (ko) | 2017-08-31 | 2020-04-29 | 아이오 테라퓨틱스, 인크. | 암 면역요법을 위해 면역 조절제와 조합된 rar 선택적 작용제 |
| WO2020148447A1 (en) | 2019-01-17 | 2020-07-23 | Debiopharm International S.A. | Combination product for the treatment of cancer |
| CA3130706A1 (en) | 2019-04-04 | 2020-10-08 | Dana-Farber Cancer Institute, Inc. | Cdk2/5 degraders and uses thereof |
| TW202120486A (zh) * | 2019-08-09 | 2021-06-01 | 英商阿帝歐斯製藥有限公司 | 新穎化合物 |
| EP4021450B1 (en) | 2019-08-26 | 2025-11-05 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| PH12022550721A1 (en) | 2019-09-25 | 2024-05-13 | Debiopharm Int Sa | Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma |
| GB201919219D0 (en) * | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| WO2021225955A1 (en) * | 2020-05-04 | 2021-11-11 | Astex Pharmaceuticals, Inc. | Iap antagonist compounds and intermediates and methods for synthesizing the same |
| PL4146617T3 (pl) * | 2020-05-04 | 2025-12-08 | Taiho Pharmaceutical Co., Ltd. | Sposoby syntezy bezwodnego kwasu mlekowego |
| TWI894285B (zh) * | 2020-06-04 | 2025-08-21 | 英屬開曼群島商百濟神州有限公司 | 作為IAP拮抗劑的吡啶並[2,3-b][1,4]噁嗪或四氫吡啶並[2,3-b][1,4]氧氮呯 |
| JP7741169B2 (ja) * | 2020-08-12 | 2025-09-17 | アーチャー－ダニエルズ－ミッドランド カンパニー | ２，５－フランジカルボン酸ジメチルエステル、及びその他のエステル化生成物の精製 |
| CA3181715A1 (en) | 2020-08-27 | 2022-03-03 | Otsuka Pharmaceutical Co., Ltd. | Biomarkers for cancer therapy using mdm2 antagonists |
| EP4211128A1 (en) * | 2020-09-14 | 2023-07-19 | Arvinas Operations, Inc. | Crystalline forms of a compound for the targeted degradation of estrogen receptor |
| GB202103080D0 (en) | 2021-03-04 | 2021-04-21 | Otsuka Pharma Co Ltd | Cancer biomarkers |
| JPWO2023022235A1 (OSRAM) | 2021-08-20 | 2023-02-23 | ||
| KR20240132251A (ko) | 2021-10-22 | 2024-09-03 | 유니버시티 오브 휴스턴 시스템 | 상피 조직의 만성 염증성 손상, 화생, 이형성증 및 암을 치료하기 위한 방법 및 조성물 |
| CA3236956A1 (en) * | 2021-11-05 | 2023-05-11 | Haihe Biopharma Co., Ltd. | Solid dispersion, preparation method therefor, and solid formulation comprising same |
| AU2023229084A1 (en) | 2022-03-04 | 2024-10-17 | Board Of Regents, The University Of Texas System | Methods of treating cancer with iap antagonist compounds and combination therapies |
| AU2023275703A1 (en) | 2022-05-23 | 2024-11-21 | Inhibrx Biosciences, Inc. | Dr5 agonist and iap antagonist combination therapy |
| WO2024047394A1 (en) | 2022-08-31 | 2024-03-07 | Otsuka Pharmaceutical Co., Ltd. | Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine |
| CN118027138A (zh) * | 2022-11-07 | 2024-05-14 | 南京中澳转化医学研究院有限公司 | 吡啶酮类化合物及其制备方法、药物组合物和应用 |
| CN116375700B (zh) * | 2023-01-10 | 2024-12-17 | 中国科学院成都生物研究所 | 一种4-氮杂吲哚啉类化合物及其合成方法与应用 |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
| TW202510888A (zh) | 2023-07-31 | 2025-03-16 | 日商大塚製藥股份有限公司 | 包含托利那泮(tolinapant)之醫藥組合物及包裝 |
| WO2025235719A1 (en) * | 2024-05-08 | 2025-11-13 | Viiv Healthcare Company | Dimeric smac mimetics useful in hiv therapy |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4080330A (en) | 1975-06-23 | 1978-03-21 | Delmar Chemicals Limited | Phenylindolines and process for their production |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| DE3822792C2 (de) | 1987-07-11 | 1997-11-27 | Sandoz Ag | Neue Verwendung von 5HT¶3¶-Antagonisten |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| TW218875B (OSRAM) | 1992-03-09 | 1994-01-11 | Takeda Pharm Industry Co Ltd | |
| WO1998004689A1 (en) | 1995-07-31 | 1998-02-05 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| NZ321575A (en) | 1995-10-30 | 1999-05-28 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives |
| ATE243697T1 (de) | 1995-12-08 | 2003-07-15 | Pfizer | Substitutierte heterozyclische derivate als crf antagonisten |
| EP0892780B1 (en) | 1996-02-22 | 2002-11-20 | Bristol-Myers Squibb Pharma Company | M-AMIDINO PHENYL ANALOGS AS FACTOR Xa INHIBITORS |
| CA2249601A1 (en) | 1996-04-03 | 1997-10-23 | Thorsten E. Fisher | Inhibitors of farnesyl-protein transferase |
| EP0912513A1 (en) | 1996-06-28 | 1999-05-06 | Merck & Co., Inc. | Fibrinogen receptor antagonist prodrugs |
| US5977134A (en) | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| TR199902590T2 (xx) | 1997-04-18 | 2000-06-21 | Smithkline Beecham P.L.C. | Birle�ik 5HT1A 5HT1B ve 5HT1D resept�r antagonist aktivitesi olan indol t�revleri. |
| AU7526798A (en) | 1997-04-18 | 1998-11-27 | Smithkline Beecham Plc | Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders |
| EP1068193A1 (en) | 1998-02-26 | 2001-01-17 | Neurogen Corporation | Benzylpiperazinyl- and benzylpiperidinyl ethanone derivatives, their preparation and their use as dopamine d 4? receptor antagonists |
| US6084098A (en) | 1999-02-26 | 2000-07-04 | Neurogen Corporation | Benzylpiperazinyl and piperidinyl ethanone derivatives: dopamine receptor subtype specific ligands |
| US6528529B1 (en) | 1998-03-31 | 2003-03-04 | Acadia Pharmaceuticals Inc. | Compounds with activity on muscarinic receptors |
| RU2230740C2 (ru) | 1998-03-31 | 2004-06-20 | Акадиа Фармасьютикалз, Инк. | Производные азотсодержащих гетероциклических соединений и фармацевтическая композиция на их основе |
| DE69934238T2 (de) | 1998-08-26 | 2007-06-21 | Aventis Pharma Ltd., West Malling | Azabicyclo-verbindungen welche die inhibition der zell adhesion modulieren |
| GB9905010D0 (en) | 1999-03-04 | 1999-04-28 | Merck Sharp & Dohme | Therapeutic agents |
| AU3555200A (en) | 1999-03-17 | 2000-10-04 | F. Hoffmann-La Roche Ag | Oxazolone derivatives and their use as alpha-1 adrenoreceptor modulators |
| GB9929552D0 (en) | 1999-12-14 | 2000-02-09 | Proteus Molecular Design | Compounds |
| AU6762400A (en) | 1999-08-12 | 2001-03-13 | Cor Therapeutics, Inc. | Inhibitors of factor xa |
| JP2003508509A (ja) | 1999-09-04 | 2003-03-04 | アストラゼネカ アクチボラグ | ピルビン酸デヒドロゲナーゼの阻害剤としてのアミド |
| GB0031088D0 (en) | 2000-12-20 | 2001-01-31 | Smithkline Beecham Plc | Medicaments |
| US20040180925A1 (en) | 2000-12-27 | 2004-09-16 | Kenji Matsuno | Dipeptidylpeptidase-IV inhibitor |
| US6790845B2 (en) | 2001-04-09 | 2004-09-14 | Bristol-Myers Squibb Pharma Company | Fused heterocyclic inhibitors of factor Xa |
| US20030095958A1 (en) | 2001-04-27 | 2003-05-22 | Bhisetti Govinda R. | Inhibitors of bace |
| CA2483253A1 (en) | 2002-04-24 | 2003-11-06 | Takeda Pharmaceutical Company Limited | Use of compounds having ccr antagonism |
| TW200402417A (en) | 2002-06-21 | 2004-02-16 | Akzo Nobel Nv | 1-[(Indol-3-yl)carbonyl]piperazine derivatives |
| KR20050114641A (ko) | 2003-03-07 | 2005-12-06 | 아스텔라스세이야쿠 가부시키가이샤 | 2,6-이치환된 스티릴을 갖는 질소 함유 헤테로환 유도체 |
| GB0307891D0 (en) | 2003-04-04 | 2003-05-14 | Angeletti P Ist Richerche Bio | Chemical compounds,compositions and uses |
| TWI372050B (en) | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| CA2533112A1 (en) | 2003-08-13 | 2005-03-03 | Christopher Hulme | Melanin concentrating hormone receptor antagonist |
| TW200524887A (en) | 2003-10-27 | 2005-08-01 | Lundbeck & Co As H | N-thiazol-2-yl-benzamide derivatives |
| WO2005097791A1 (en) | 2004-04-07 | 2005-10-20 | Novartis Ag | Inhibitors of iap |
| WO2006014361A1 (en) * | 2004-07-02 | 2006-02-09 | Genentech, Inc. | Inhibitors of iap |
| US7674787B2 (en) | 2004-07-09 | 2010-03-09 | The Regents Of The University Of Michigan | Conformationally constrained Smac mimetics and the uses thereof |
| WO2006032987A1 (en) | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Indoline compounds and their use in the treatment of arteriosclerosis |
| EA019420B1 (ru) | 2004-12-20 | 2014-03-31 | Дженентех, Инк. | Пирролидиновые ингибиторы иап (ингибиторов апоптоза) |
| DK1851200T3 (da) | 2005-02-25 | 2014-04-14 | Tetralogic Pharm Corp | Dimere iap-inhibitorer |
| CA2627426A1 (en) | 2005-11-11 | 2007-05-18 | Markus Boehringer | Carbocyclic fused cyclic amines as inhibitors of the coagulation factor xa |
| CN101374829A (zh) | 2005-12-19 | 2009-02-25 | 健泰科生物技术公司 | Iap的抑制剂 |
| AU2006327243A1 (en) | 2005-12-21 | 2007-06-28 | Decode Genetics Ehf | N-linked aryl heteroaryl inhibitors of LTA4H for treating inflammation |
| FR2896504B1 (fr) | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| GB0602335D0 (en) | 2006-02-07 | 2006-03-15 | Remynd Nv | Thiadiazole Derivatives For The Treatment Of Neurodegenerative Diseases |
| EP2029592A1 (en) | 2006-04-25 | 2009-03-04 | Astex Therapeutics Limited | Pharmaceutical compounds |
| JP5452223B2 (ja) * | 2006-07-24 | 2014-03-26 | テトラロジック ファーマシューティカルズ コーポレーション | Ｉａｐ阻害剤 |
| JP5190062B2 (ja) | 2006-10-12 | 2013-04-24 | ノバルティス アーゲー | Ｉａｐ阻害剤としてのピロリジン誘導体 |
| US8048886B2 (en) | 2006-12-07 | 2011-11-01 | Novartis Ag | Substituted pyrazine-3-one-derivatives as IAP inhibitors |
| CA2680177A1 (en) | 2007-03-07 | 2008-09-12 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors containing a heterocyclic moiety |
| US8173645B2 (en) | 2007-03-21 | 2012-05-08 | Takeda San Diego, Inc. | Glucokinase activators |
| CL2008002319A1 (es) | 2007-08-08 | 2009-01-02 | Mithkline Beecham Corp | Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer. |
| WO2009067233A1 (en) | 2007-11-20 | 2009-05-28 | Millennium Pharmaceuticals, Inc. | Beta carbolines and uses thereof |
| BRPI0906785A2 (pt) | 2008-01-24 | 2015-07-14 | Tetralogic Pharm Corp | Composto, composição farmacêutica, e, métodos para induzir a apoptose em uma célula, para tratar câncer e uma doença autoimune |
| WO2009147476A1 (en) | 2008-06-02 | 2009-12-10 | Matrix Laboratories Ltd. | Novel pde inhibitors, pharmaceutical compositions containing them and processes for their preparation |
| GB0810902D0 (en) * | 2008-06-13 | 2008-07-23 | Astex Therapeutics Ltd | New compounds |
| WO2010011666A2 (en) | 2008-07-21 | 2010-01-28 | University Of South Florida | Indoline scaffold shp-2 inhibitors and cancer treatment method |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| DE102008059578A1 (de) | 2008-11-28 | 2010-06-10 | Merck Patent Gmbh | Benzo-Naphtyridin Verbindungen |
| KR20130130875A (ko) | 2009-02-27 | 2013-12-02 | 이난타 파마슈티칼스, 인코포레이티드 | Ｃ형 간염 바이러스 억제제 |
| WO2010121212A2 (en) | 2009-04-17 | 2010-10-21 | H. Lee Moffit Cancer Center And Research Institute, Inc. | Indoline scaffold shp-2 inhibitors and method of treating cancer |
| WO2010129467A1 (en) | 2009-05-04 | 2010-11-11 | Plexxikon, Inc. | Compounds and methods for inhibition of renin, and indications therefor |
| JP5642777B2 (ja) | 2009-05-28 | 2014-12-17 | テトラロジック ファーマシューティカルズ コーポレーション | Ｉａｐ阻害剤 |
| UY33794A (es) * | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
| GB201106817D0 (en) * | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
| GB201106814D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compounds |
| EP2763531A4 (en) | 2011-10-03 | 2015-11-18 | Univ Columbia | NEW MOLECULES FOR THE SELECTIVE INHIBITION OF HISTONDEACETYLASE 6 IN RELATION TO HISTONDEACETYLASE 1 |
| PT2800738T (pt) | 2012-01-06 | 2020-06-23 | Novartis Ag | Compostos heterocíclicos e métodos para a utilização dos mesmos |
| GB201218862D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| US9980973B2 (en) | 2012-10-19 | 2018-05-29 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218850D0 (en) * | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| GB201218864D0 (en) * | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
| LT3083616T (lt) * | 2013-12-20 | 2021-09-10 | Astex Therapeutics Limited | Bicikinių heterociklų junginiai ir jų panaudojimas terapijoje |
| CA2935944A1 (en) | 2014-01-09 | 2015-07-16 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Substituted benzoxazine and related compounds |
| WO2021225955A1 (en) | 2020-05-04 | 2021-11-11 | Astex Pharmaceuticals, Inc. | Iap antagonist compounds and intermediates and methods for synthesizing the same |
| PL4146617T3 (pl) | 2020-05-04 | 2025-12-08 | Taiho Pharmaceutical Co., Ltd. | Sposoby syntezy bezwodnego kwasu mlekowego |
| AU2023229084A1 (en) | 2022-03-04 | 2024-10-17 | Board Of Regents, The University Of Texas System | Methods of treating cancer with iap antagonist compounds and combination therapies |
| WO2024047394A1 (en) | 2022-08-31 | 2024-03-07 | Otsuka Pharmaceutical Co., Ltd. | Combination therapies for treatment of t-cell lymphomas with tolinapant, cedazuridine and decitabine |
-
2014
- 2014-12-19 LT LTEPPCT/GB2014/053778T patent/LT3083616T/lt unknown
- 2014-12-19 BR BR122022015241-4A patent/BR122022015241B1/pt active IP Right Grant
- 2014-12-19 SG SG10201808102WA patent/SG10201808102WA/en unknown
- 2014-12-19 EP EP14815838.9A patent/EP3083616B1/en active Active
- 2014-12-19 CN CN201811129977.8A patent/CN109336883B/zh active Active
- 2014-12-19 SM SM20210497T patent/SMT202100497T1/it unknown
- 2014-12-19 HR HRP20211406TT patent/HRP20211406T1/hr unknown
- 2014-12-19 SI SI201431877T patent/SI3083616T1/sl unknown
- 2014-12-19 DK DK14815838.9T patent/DK3083616T3/da active
- 2014-12-19 PT PT148158389T patent/PT3083616T/pt unknown
- 2014-12-19 CA CA2933939A patent/CA2933939C/en active Active
- 2014-12-19 KR KR1020167019182A patent/KR102408262B1/ko active Active
- 2014-12-19 HU HUE14815838A patent/HUE056297T2/hu unknown
- 2014-12-19 PL PL14815838T patent/PL3083616T3/pl unknown
- 2014-12-19 MY MYPI2020002540A patent/MY193649A/en unknown
- 2014-12-19 AU AU2014369446A patent/AU2014369446C1/en active Active
- 2014-12-19 BR BR112016014561-5A patent/BR112016014561B1/pt active IP Right Grant
- 2014-12-19 SG SG11201604795RA patent/SG11201604795RA/en unknown
- 2014-12-19 EP EP19219371.2A patent/EP3686200A3/en active Pending
- 2014-12-19 CN CN202210613741.1A patent/CN115368356B/zh active Active
- 2014-12-19 US US15/105,360 patent/US9783538B2/en active Active
- 2014-12-19 CN CN201480069940.4A patent/CN105829310B/zh active Active
- 2014-12-19 RS RS20211096A patent/RS62301B1/sr unknown
- 2014-12-19 WO PCT/GB2014/053778 patent/WO2015092420A1/en not_active Ceased
- 2014-12-19 MX MX2016008131A patent/MX380469B/es unknown
- 2014-12-19 NZ NZ71990514A patent/NZ719905A/en unknown
- 2014-12-19 JP JP2016541373A patent/JP6470756B2/ja active Active
- 2014-12-19 ES ES14815838T patent/ES2883289T3/es active Active
- 2014-12-19 RU RU2016129472A patent/RU2696310C1/ru active
- 2014-12-19 NZ NZ758528A patent/NZ758528A/en unknown
- 2014-12-19 TW TW103144450A patent/TWI649319B/zh active
- 2014-12-19 MY MYPI2016701668A patent/MY186311A/en unknown
-
2016
- 2016-06-13 PH PH12016501139A patent/PH12016501139B1/en unknown
- 2016-06-15 IL IL246239A patent/IL246239B/en active IP Right Grant
- 2016-06-19 SA SA516371360A patent/SA516371360B1/ar unknown
-
2017
- 2017-08-11 US US15/675,052 patent/US10618895B2/en active Active
-
2019
- 2019-01-17 JP JP2019005876A patent/JP6735369B2/ja active Active
- 2019-02-07 AU AU2019200840A patent/AU2019200840C1/en active Active
-
2020
- 2020-02-19 US US16/795,117 patent/US11225476B2/en active Active
- 2020-07-10 JP JP2020119260A patent/JP7110279B2/ja active Active
-
2021
- 2021-08-12 CY CY20211100729T patent/CY1124436T1/el unknown
- 2021-12-07 US US17/643,083 patent/US11643410B2/en active Active
-
2022
- 2022-12-21 US US18/069,571 patent/US12202828B2/en active Active
-
2024
- 2024-12-09 US US18/973,574 patent/US20250296930A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017500338A5 (OSRAM) | ||
| HRP20211406T1 (hr) | Biciklični heterociklični spojevi i njihove uporabe u liječenju | |
| RU2702906C2 (ru) | Птеридины в качестве fgfr ингибиторов | |
| AU2006331912B2 (en) | Triazolopyridazines as tyrosine kinase modulators | |
| JP7158286B2 (ja) | ＰＩ３Ｋβ阻害剤としてのアザベンゾイミダゾール誘導体 | |
| JP2021020948A (ja) | Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法 | |
| KR20180094976A (ko) | Tank-결합 키나제 억제제 화합물 | |
| BR112020015056A2 (pt) | Moduladores de receptor de quimiocina e usos dos mesmos | |
| CA3110502A1 (en) | Pyrazolo[3,4-b]pyridine compounds as inhibitors of tam and met kinases | |
| CN104936953B (zh) | 化合物 | |
| PE20090506A1 (es) | DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZIN COMO INHIBIDORES DE ALK5 Y/O ALK4 | |
| EP2203442B1 (en) | Substituted pyrrolo-pyrimidine derivatives, process for their preparation and their use as kinase inhibitors | |
| ES2811845T3 (es) | Heterociclos tricíclicos para el tratamiento del cáncer | |
| JP7244504B2 (ja) | ＰＩ３Ｋ－γ阻害剤としての三級ヒドロキシ基で置換された縮合イミダゾール誘導体 | |
| TW201202222A (en) | Inhibitors of HCV NS5A | |
| JP2015506985A5 (OSRAM) | ||
| CN107548391A (zh) | 嘧啶或吡啶类化合物、其制备方法和医药用途 | |
| KR20120062839A (ko) | 단백질 키나제 억제제로서의 화합물 및 조성물 | |
| JP2018507877A5 (OSRAM) | ||
| JP2017516775A5 (OSRAM) | ||
| JP2013512268A5 (OSRAM) | ||
| WO2018049271A1 (en) | Chemokine receptor modulators and uses thereof | |
| EP2702055A1 (en) | Pyrazolyl-pyrimidine derivatives as kinase inhibitors | |
| JP2016503779A5 (OSRAM) | ||
| JP2016528298A5 (OSRAM) |